Aficamten Sales Market Forecast

Key Factors Driving Aficamten Growth

Market Share Gains and New Patient Starts

• Aficamten, a next-generation selective cardiac myosin inhibitor developed by Cytokinetics, is gaining strong traction in the hypertrophic cardiomyopathy (HCM) space, particularly in obstructive HCM (oHCM).
• Increasing physician interest is being driven by its predictable pharmacokinetics and rapid, reversible cardiac effects, which may simplify dose titration compared with first-generation agents.
• Anticipated regulatory approval and growing awareness among cardiologists are expected to translate into accelerated new patient starts, especially among symptomatic oHCM patients inadequately controlled on beta-blockers or calcium channel blockers.

Expansion Across Key Indications

• Obstructive Hypertrophic Cardiomyopathy (oHCM): Aficamten is positioned as a potentially best-in-class therapy for symptomatic oHCM, supported by strong Phase III efficacy data demonstrating meaningful improvements in exercise capacity, LVOT gradients, and symptoms.
• Earlier-Line Use Potential: Favorable safety and reversibility profile may support use earlier in the treatment paradigm, potentially before septal reduction therapy.
• Non-Obstructive HCM (nHCM): Although clinical outcomes have been more challenging in this segment, continued learnings may inform future development strategies.
• Pipeline Optionality: Success in oHCM may enable lifecycle expansion into broader cardiomyopathy or heart failure populations over time.

Geographic Expansion

• Initial Focus on the U.S. and Europe: Commercial strategy is centered on major cardiology markets with established HCM diagnosis infrastructure and specialist centers.
• Global Expansion Potential: Following initial approvals, expansion into Asia-Pacific markets is expected, supported by increasing recognition and diagnosis of HCM in countries such as Japan and China.
• Specialty-Driven Uptake: Adoption will be driven through HCM centers of excellence, cardiology specialists, and integrated heart failure clinics.

New Indication Approvals

• Regulatory Filings for oHCM: Positive Phase III data support regulatory submissions for symptomatic obstructive HCM, which would mark a significant milestone for Cytokinetics.
• Label Expansion Opportunities: Additional studies and post-marketing data could support expanded labeling related to disease severity or treatment lines.
• Portfolio Diversification: Approval would significantly strengthen Cytokinetics’ cardiovascular franchise and diversify revenue beyond development-stage assets.

Strong oHCM Volume Momentum

• High Unmet Need: Obstructive HCM remains underserved, with many patients remaining symptomatic despite standard therapies.
• Compelling Clinical Benefits: Improvements in peak oxygen consumption (pVO₂), NYHA class, and quality-of-life measures are expected to drive sustained prescription momentum.
• Long-Term Adoption Potential: As familiarity increases and real-world experience accumulates, aficamten could become a cornerstone oral therapy in oHCM management.

Competitive Differentiation and Market Trends

• Next-Generation Cardiac Myosin Inhibitor: Aficamten offers shorter half-life and precise on/off control, differentiating it from earlier agents in the class.
• Simplified Dosing and Monitoring: Reduced risk of prolonged systolic dysfunction may lower monitoring burden, enhancing physician and patient confidence.
• Shift Toward Disease-Specific Therapies: Broader market trends favor targeted, mechanism-based cardiovascular drugs over nonspecific symptom control.
• Growing Role of Real-World Evidence (RWE): Post-approval RWE will be critical in shaping payer coverage, treatment algorithms, and long-term adoption.

Aficamten Recent Developments

Cytokinetics announced positive topline results from the Phase III SEQUOIA-HCM trial, demonstrating that Aficamten met its primary and key secondary endpoints in patients with symptomatic obstructive HCM, including significant improvements in exercise capacity and LVOT gradients. These results support planned regulatory submissions in the US and other major markets. In contrast, the ODYSSEY-HCM trial in non-obstructive HCM did not meet its primary endpoint, leading the company to prioritize oHCM as the core commercial indication.

“Aficamten Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Aficamten for approved indication like Hypertrophic cardiomyopathy in the 7MM. A detailed picture of Aficamten’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Aficamten for approved indications. The Aficamten market report provides insights about Aficamten’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Aficamten performance, future market assessments inclusive of the Aficamten market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Aficamten sales forecasts, along with factors driving its market.

Aficamten Drug Summary

Aficamten is an oral small-molecule cardiac myosin inhibitor developed by Cytokinetics and marketed as MYQORZO. Approved by the FDA in December 2025 for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), it reduces excessive myocardial contractility by binding to the myosin motor domain, stabilizing a weak actin-binding state, and decreasing the number of force-generating myosin heads. This mechanism improves symptoms like shortness of breath and fatigue, enhances exercise capacity, and alleviates left ventricular outflow tract obstruction without significantly affecting calcium transients or requiring extensive titration due to its favorable pharmacokinetics, including once-daily dosing and rapid steady-state attainment. The report provides Aficamten’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Aficamten Market Report

The report provides insights into:

• A comprehensive product overview including the Aficamten MoA, description, dosage and administration, research and development activities in approved indication like Hypertrophic cardiomyopathy.
• Elaborated details on Aficamten regulatory milestones and other development activities have been provided in Aficamten market report.
• The report also highlights Aficamten‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The Aficamten market report also covers the patents information, generic entry and impact on cost cut.
• The Aficamten market report contains current and forecasted Aficamten sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Aficamten market report also features the SWOT analysis with analyst views for Aficamten in approved indications.

Aficamten Methodology

The Aficamten market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases. 

Aficamten Analytical Perspective by DelveInsight

In-depth Aficamten Market Assessment

This Aficamten sales market forecast report provides a detailed market assessment of Aficamten for approved indication like Hypertrophic cardiomyopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Aficamten sales data uptil 2034.

Aficamten Clinical Assessment

The Aficamten market report provides the clinical trials information of Aficamten for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

Aficamten Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Aficamten Market Potential & Revenue Forecast

• Projected market size for the Aficamten and its key indications
• Estimated Aficamten sales potential (Aficamten peak sales forecasts)
• Aficamten Pricing strategies and reimbursement landscape

Aficamten Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Aficamten Market positioning compared to existing treatments
• Aficamten Strengths & weaknesses relative to competitors

Aficamten Regulatory & Commercial Milestones

• Aficamten Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Aficamten Clinical Differentiation

• Aficamten Efficacy & safety advantages over existing drugs
• Aficamten Unique selling points

Aficamten Market Report Highlights

• In the coming years, the Aficamten market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Aficamten companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Aficamten’s dominance.
• Other emerging products for Hypertrophic cardiomyopathy are expected to give tough market competition to Aficamten and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Aficamten in approved indications.
• Analyse Aficamten cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Aficamten sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Aficamten in approved indications.

Key Questions Answered in the Aficamten Market Report

• What is the class of therapy, route of administration and mechanism of action of Aficamten? How strong is Aficamten’s clinical and commercial performance?
• What is Aficamten’s clinical trial status in each individual indications such as Hypertrophic cardiomyopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Aficamten Manufacturers?
• What are the key designations that have been granted to Aficamten for approved indications? How are they going to impact Aficamten’s penetration in various geographies?
• What is the current and forecasted Aficamten market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Aficamten in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• What are the other emerging products available and how are these giving competition to Aficamten for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is Aficamten? What is the duration of therapy and what are the geographical variations in cost per patient?